Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Neoplasm Metastasis 1Gastrointestinal Diseases 1Digestive System Diseases 1

Interventions

Oxaliplatin 300Fluorouracil 273Bevacizumab 238Gemcitabine 236Leucovorin 213Capecitabine 207pembrolizumab 202Irinotecan 159Nivolumab 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 119Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
IDRX-42 × Gastrointestinal × 1 year × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05489237 2026-05-04

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1 Recruiting
278 enrolled
GastrointestinalSarcoma

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡